Business
Novo Nordisk Investors Demand Greater Dealmaking and Drug Pipeline Innovation
Investors urge Novo Nordisk to pursue more acquisitions and develop new drugs to sustain long-term growth.
Investors urge Novo Nordisk to pursue more acquisitions and develop new drugs to sustain long-term growth.